RNA viruses expressing IL-12 for immunovirotherapy

Patent metadata

Field	Value
Publication number	US-10344067-B2
Application number	US-201715441545-A
Country	US
Kind code	B2
Filing date	Feb 24, 2017
Priority date	Feb 25, 2016
Publication date	Jul 9, 2019
Grant date	Jul 9, 2019

Abstract

The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.

First claim

The claimed invention is:

1. A recombinant virus of the family Paramyxoviridae comprising at least one expressible polynucleotide encoding an interleukin 12 (IL-12) polypeptide wherein said IL-12 polypeptide is a fusion protein comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12, wherein said polynucleotide optionally encodes a ligand for an immune checkpoint blockade protein or a binding domain to a tumor associated antigen, and wherein said recombinant virus is encoded by a polynucleotide comprising the nucleic acid sequence selected from the group consisting of SEQ ID NOS 4 to 7, 14 and 15.

2. A host cell comprising the recombinant virus of the family Paramyxoviridae according to claim 1 .

3. A medicament comprising
(a) (i) the recombinant virus of the family Paramyxoviridae according to claim 1 ; and/or
(a)(ii) a host cell comprising the recombinant virus of the family Paramyxoviridae according to claim 1 ; and
(b) at least one pharmacological acceptable excipient.

4. A method for treating cancer in a subject afflicted with cancer, comprising administering to said subject a therapeutically effective amount of the medicament according to claim 3 , thereby treating cancer in a subject afflicted with cancer.

5. The method of claim 4 , wherein said cancer is a solid cancer, a metastasis, or a relapse thereof.

6. The method of claim 4 , wherein treating cancer is reducing tumor burden.

7. The method of claim 4 , wherein said cancer is malignant melanoma, head and neck cancer, hepatocellular carcinoma, pancreatic carcinoma, prostate cancer, renal cell carcinoma, gastric carcinoma, colorectal carcinoma, lymphomas or leukemias.

Assignees

• Deutsches Krebsforsch
• Ruprecht Karls Univ

Inventors

• Ungerechts Guy
• Engeland Christine
• Veinalde Ruta

Classifications

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• C07K16/2887

  against CD20 · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• C07K16/3007

  Carcino-embryonic Antigens · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title